Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16997310 | 0.91 | SIGMAR1 (0.52) | SIGMAR1NPY5RAVPR1AHRH3 | |
| SCHEMBL8913424 | 0.83 | SIGMAR1 (0.62) | SIGMAR1NPY5RAVPR1AHRH3 | |
| SCHEMBL3774009 | 0.82 | SIGMAR1 (0.53) | SIGMAR1NPY5RHRH3 | |
| SCHEMBL9963270 | 0.82 | HSD11B1 (0.49) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL12568770 | 0.80 | HRH3 (0.52) | SIGMAR1NPY5RAVPR1AHRH3 | |
| SCHEMBL8777675 | 0.80 | SIGMAR1 (0.61) | SIGMAR1NPY5RAVPR1A | |
| SCHEMBL14543925 | 0.79 | SIGMAR1 (0.70) | SIGMAR1NPY5RAVPR1AHRH3 | |
| SCHEMBL8110392 | 0.79 | SIGMAR1 (0.58) | SIGMAR1NPY5RAVPR1AHRH3 | |
| SCHEMBL19398514 | 0.78 | SIGMAR1 (0.61) | SIGMAR1NPY5RAVPR1AHRH3 | |
| SCHEMBL12230594 | 0.78 | PLD2 (0.53) | SIGMAR1AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| EP-2864331-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9682980-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150366987-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-04 | — | — | US | disclosed |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | UNIV QUEENSLAND (AU) | 2015-02-05 | — | — | US | disclosed |
| US-8927503-B2 | Modulations of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-06 | — | — | US | disclosed |
| US-8901085-B2 | — | — | 2014-12-02 | — | — | US | disclosed |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629353-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | SIGMAR1 44/4885NPY5R 200/4885AVPR1A 1/4885 |
| US-20100120751-A1 | SPIRO-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENES | AVPR1A, OXTR, AVPR1B | SIGMAR1 123/4885NPY5R 14/4885AVPR1A 1/4885 |
| US-20150152113-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2A | SIGMAR1 161/4885NPY5R 949/4885AVPR1A 757/4885 |
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | SIGMAR1 1623/4885NPY5R 766/4885AVPR1A 364/4885 |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | SIGMAR1 1668/4885NPY5R 660/4885AVPR1A 483/4885 |
| US-20150366987-A1 | MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF | ERBB2, EGFR, ERBB3 | SIGMAR1 4553/4885NPY5R 1212/4885AVPR1A 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.